Abstracts Archive - Page 1204 of 2425 - ACR Meeting Abstracts

Abstract Number: 2993 • 2018 ACR/ARHP Annual Meeting
Vascular Involvement in Behcet’s Syndrome May be Associated with Subclinical Atherosclerosis
Emine USLU YURTERI¹, EVREN ÜSTÜNER², Murat TORGUTALP¹, Mucteba Enes YAYLA¹, Ilyas Ercan OKATAN¹, Ayse Bahar KELESOGLU DINCER¹, Serdar SEZER¹, Emine Gozde AYDEMIR GULOKSUZ¹, Tahsin Murat TURGAY¹, Gülay KINIKLI³ and Aşkın Ateş⁴, ¹Department of Internal Medicine, Division of Rheumatology, Ankara University School of Medicine Department of Internal Medicine, Division of Rheumatology, ANKARA, Turkey, ²RADIOLOGY, ANKARA UNIVERSITY RADIOLOGY DEPARTMENT, ANKARA, Turkey, ³Department of Internal Medicine, Division of Rheumatology, Ankara University School of Medicine Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁴Department of Internal Medicine, Division of Rheumatology, Ankara University School of Medicine, Ankara, Turkey
Background/Purpose: Behçet's Syndrome (BS) is a vasculitic process which is characterized by recurrent oral and genital aphthous ulcerations, ocular, vascular, neurological, and gastrointestinal involvement .…
Abstract Number: 2994 • 2018 ACR/ARHP Annual Meeting
Costs Associated with Non-Medical Switching from Originator to Biosimilar Etanercept in Patients with Rheumatoid Arthritis in the UK
Kateryna Onishchenko¹, Stamatia Theodora Alexopoulos¹, Cinzia Curiale² and Miriam Tarallo², ¹Consulting at McCann Health, London, United Kingdom, ²Pfizer, Rome, Italy
Background/Purpose: To estimate the cost impact of non-medical switching from originator etanercept (ETN) to biosimilar ETN in patients with rheumatoid arthritis (RA) in the UK.…
Abstract Number: 2995 • 2018 ACR/ARHP Annual Meeting
Healthcare Cost of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis
Jennie H. Best¹, Amanda Kong², David Smith², Ibrahim Abbass¹ and Margaret Michalska¹, ¹Genentech, Inc., South San Francisco, CA, ²IBM Watson Health, Bethesda, MD
Background/Purpose: To quantify the healthcare expenditures associated with oral glucocorticoids-related-adverse events (OGCs-AEs), among patients in the US with giant cell arteritis (GCA) using claims data…
Abstract Number: 2996 • 2018 ACR/ARHP Annual Meeting
The Economic Burden of Systemic Lupus Erythematosus (SLE) within a Medicaid Cohort Stratified By Disease Severity
Karen Costenbader¹, Shaum Kabadi², Emily Durden³, Isabelle Winer³, Kirstin Bacani², Jinoos Yazdany⁴ and Ann E. Clarke⁵, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²AstraZeneca, Gaithersburg, MD, ³Truven Health Analytics an IBM Company, Ann Arbor, MI, ⁴University of California, San Francisco, San Francisco, CA, ⁵Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Estimates of the economic burden of SLE within economically disadvantaged populations in the US are limited. The purpose of this study is to provide…
Abstract Number: 2997 • 2018 ACR/ARHP Annual Meeting
Association between Payments By Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology
Ali Duarte-Garcia¹, Cynthia S. Crowson², Rozalina McCoy¹, Joseph Ross³, Eric L. Matteson⁴ and Nilay Shah⁵, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Yale Univeristy, New Haven, CT, ⁴Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵Health Care Policy and Research, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Prescription drugs are the third largest category of healthcare spending in the US. Four of the top five costliest drugs are biologics used for…
Abstract Number: 2998 • 2018 ACR/ARHP Annual Meeting
Opioid Use Among SLE Patients and Controls in the Population-Based Michigan Lupus Epidemiology & Surveillance (MILES) Cohort
Jiha Lee¹, Amrita Padda², Wendy Marder³, Siobán Harlow⁴, Afton L. Hassett⁵, Suzanna Zick⁶, Charles G. Helmick⁷, Kamil E. Barbour⁷, Caroline Gordon⁸, Deeba Minhas³, W. Joseph McCune³ and Emily C. Somers³, ¹Rheumatology, University of Michigan School of Medicine, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Epidemiology Department- School of Public Health, Obstetrics and Gynecology- Medical School, University of Michigan, Ann Arbor, MI, ⁵Anesthesiology, University of Michigan, Ann Arbor, MI, ⁶Department of Family Medicine, University of Michigan, Ann Arbor, MI, ⁷Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ⁸Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: SLE patients frequently experience pain. Opioid use for the management of chronic pain has been associated with increased morbidity, mortality, and healthcare resource utilization.…
Abstract Number: 2999 • 2018 ACR/ARHP Annual Meeting
Does the Incremental Cost of ACPA-Positive Rheumatoid Arthritis Patients Vary By the Care Pathway They Follow?
Aniket Kawatkar¹, J An², TC Cheetham², Kiran Gupta³, Alexander Marshall⁴, Eric Haupt¹, Gary Okano³ and Tammy Curtice⁵, ¹Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, ²Western University of Health Sciences, Pomona, CA, ³HEOR, Bristol-Myers Squibb, Princeton, NJ, ⁴HEOR, Bristol-Myers Squibb, Lawrenceville, NJ, ⁵Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Rheumatoid Arthritis (RA) patients who are anti-citrullinated peptide antibody (ACPA) positive are prone to more severe structural damage, radiographic progression and inferior response to…
Abstract Number: 1L • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Intra-Articular Sprifermin in Symptomatic Radiographic Knee Osteoarthritis: Results of the 2-Year Primary Analysis from a 5-Year Randomised, Placebo-Controlled, Phase II Study
Marc C. Hochberg¹, Ali Guermazi², Hans Guehring³, Aida Aydemir⁴, Stephen Wax⁵, Patricia Fleuranceau-Morel⁴, Asger Reinstrup Bihlet⁶, Inger Byrjalsen⁶, Jeppe Ragnar Andersen⁶ and Felix Eckstein⁷, ¹University of Maryland School of Medicine, Baltimore, MD, ²Boston Imaging Core Lab, LLC, and Boston University School of Medicine, Boston, MA, ³Merck KGaA, Darmstadt, Germany, ⁴EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁵EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA, ⁶Nordic Bioscience, Herlev, Denmark, ⁷Institute of Anatomy, Paracelsus Medical University, Salzburg, Austria

Background/Purpose: Sprifermin, a novel recombinant human fibroblast growth factor-18 is currently investigated as a potential disease-modifying osteoarthritis (OA) drug. Two-year primary data from a 5-year…
Abstract Number: 2L • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety Results from a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor, in Patients with Active Psoriatic Arthritis
Philip J Mease¹, Herbert Kellner², Akimichi Morita³, Alan J. Kivitz⁴, Kim A. Papp⁵, Stella Aslanyan⁶, Beate Berner⁷, Kun Chen⁸, Ann Eldred⁸ and Frank Behrens⁹, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Private Practice and Division of Rheumatology KHI Neuwittelsbach, München, Germany, ³Dept of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵K Papp Clinical Research and Probity Medical Research Inc, Waterloo, ON, Canada, ⁶Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁷Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ⁸AbbVie Inc., North Chicago, IL, ⁹CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany

Background/Purpose: Interleukin-23 (IL-23), a key regulator of multiple effector cytokines (including IL-17, IL-22, and TNF), has been implicated in psoriatic lesions, synovitis, enthesitis, and bone…
Abstract Number: 3L • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Low Radiographic Progression and Sustained Efficacy through 4 Years in Patients with Active Ankylosing Spondylitis
Jürgen Braun¹, Xenofon Baraliakos¹, Atul A. Deodhar², Denis Poddubnyy³, Paul Emery⁴, Evie Maria Delicha⁵, Zsolt Talloczy⁶ and Brian Porter⁶, ¹Rheumazentrum Ruhrgebiet, Herne, and Ruhr University Bochum, Herne, Germany, ²Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ³Department of Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Leeds Musculoskeletal Biomedical Research Unit/Institute Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ

Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, reported improved signs and symptoms of ankylosing spondylitis (AS) in the MEASURE 1 trial.1 Here, we report…
Abstract Number: 4L • 2017 ACR/ARHP Annual Meeting
Final Results of an Open Label Phase 2 Study of a Reversible B Cell Inhibitor, Xmab®5871, in IgG4-Related Disease
John H. Stone¹, Zachary S. Wallace², Cory A. Perugino³, Ana D. Fernandes⁴, Payal Patel⁵, Paul A. Foster⁶ and Debra J. Zack⁶, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ⁵Rheumatology, Harvard, Boston, MA, ⁶Xencor, Inc., San Diego, CA

Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated condition causing fibro-inflammatory lesions that can lead to irreversible organ damage and death. No approved therapies exist. A…
Abstract Number: 5L • 2017 ACR/ARHP Annual Meeting
Rapamycin Vs. Placebo for the Treatment of Inclusion Body Myositis: Improvement of the 6 Min Walking Distance, a Functional Scale, the FVC and Muscle Quantitative MRI
Olivier Benveniste¹, Jean-Yves Hogrel², Melanie Annoussamy², Damien Bachasson², Aude Rigolet³, Laurent Servais², Joe-Elie Salem⁴, Baptiste Hervier³, Oceane Landon Cardinal⁵, Kuberaka Mariampillai¹, Jean-Sebastien hulot⁴, Pierre Carlier² and Yves Allenbach⁶, ¹Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), Paris, France, Paris, France, ²Institute of Myology, Paris, France, ³Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁴INSERM, CIC-1421, Paris, France, ⁵Internal Medicine, Assistance Public - Hopitaux de Paris, Pitié-Salpêtrire University Hospital, Paris, France, ⁶Internal Medicine, Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France

Background/Purpose: Inclusion body Myositis (IBM) is the most frequent myositis in patients over 50 years old. Conventional immunosuppressive drugs are today ineffective or even aggravate…
Abstract Number: 6L • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Ustekinumab, an Interleukin 12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Results of a Phase 2, Randomized Placebo-Controlled Study
Ronald van Vollenhoven¹, Bevra H. Hahn², George C. Tsokos³, Carrie Wagner⁴, Peter Lipsky⁵, Benjamin Hsu⁴, Marc Chevrier⁴, Robert Gordon⁴, Manon Triebel⁶ and Shawn Rose⁴, ¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²UCLA David Geffen School of Medicine, Los Angeles, CA, ³Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Ampel BioSolutions LLC, Charlottesville, VA, ⁶Janssen Biologics Europe, Leiden, Netherlands

Background/Purpose: The IL-12/23 pathway has been implicated in the pathogenesis of SLE. The anti-IL12/23 monoclonal antibody ustekinumab (UST) is efficacious in the treatment of psoriasis,…
Abstract Number: 7L • 2017 ACR/ARHP Annual Meeting
A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis
Victoria P. Werth¹, Emily Hejazi², Sandra M. Pena¹, Jessica S. Haber³, Joyce Okawa¹, Rui Feng⁴, Kirubel Gabre², Josef Concha², Caitlin Cornwall⁵, Nancy Dgetluck⁶, Scott Constantine⁵ and Barbara White⁵, ¹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ⁴Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵Corbus Pharmaceuticals, Inc., Norwood, MA, ⁶Biostatistics, Corbus Pharmaceuticals, Inc., Norwood, MA

Background/Purpose: Effective treatment options are limited for refractory skin disease in dermatomyositis (DM). Anabasum is a non-immunosuppressive, synthetic, oral preferential CB2 agonist that triggers resolution…
Abstract Number: 8L • 2017 ACR/ARHP Annual Meeting
Prevalence of Blindness in a Cohort of Rheumatologic Patients Treated with Hydroxychloroquine
Dilpreet Singh¹, Leila Muhieddine², Douglas Einstadter³ and Stanley Ballou⁴, ¹Rheumatology, Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, OH, ²Internal Medicine, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, ³Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ⁴Rheumatology, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH

Background/Purpose: Hydroxychloroquine (HCQ) is widely used in the treatment of chronic rheumatic diseases. Its long-standing use has been associated with retinopathy in a daily and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].